Karaarslan Serap, Genç Berhan, Nart Ahmet, Börekçi İsmail, Buğdayci Mehmet Hüsnü
Department of Pathology, Şifa University Faculty of Medicine, İZMİR, Turkey.
Turk Patoloji Derg. 2016;32(1):8-14. doi: 10.5146/tjpath.2015.01342.
We aimed to find the relationship between parafibromin expression and clinicopathologic variables of breast carcinoma.
Ninety-seven cases of invasive breast carcinoma diagnosed at our department between the years 2010-2013 were included in the study. The parafibromin expression state was compared with the estrogen receptor, progesterone receptor, cerbB2, Ki67 results, and the clinicopathological variables.
Among 97 breast carcinoma cases, 66 (68%) were invasive ductal carcinoma. The average age was 54.3 (min:25, max:100), and the average tumor size was 31.1 mm (min:7, max:120). Lymph node metastasis was detected in 58% of the cases. Eleven were diagnosed with metastasis amongst 77 cases whose distant metastasis data could be reached. Eleven cases were lost due to breast carcinoma. As the tumor grade increased, the possibility of distant metastasis and lymph node metastasis increased as well (p=0.04, p=0.05, respectively). The mean follow-up duration of the cases was 26.6 ± 9.8 (min. 6, max. 53) months, and there was no significant difference in survival between the other variables. Of the cases, 21.6% were negative, 9.3% were (+) positive, 11.3% were (++) positive and 57.7% were (+++) positive for parafibromin. It was found that there was an inverse correlation between the Ki67 proliferation index and lymph node metastasis and the parafibromin expression (p=0.018, p=0.029, respectively).
We suggest that parafibromin may be a possible prognostic and predictive parameter for breast carcinomas. As the data on this matter in the literature is limited, it would be beneficial to investigate the matter and evaluate its relationship with survival in larger series.
我们旨在探寻副纤维蛋白表达与乳腺癌临床病理变量之间的关系。
本研究纳入了2010年至2013年间在我科诊断的97例浸润性乳腺癌病例。将副纤维蛋白表达状态与雌激素受体、孕激素受体、cerbB2、Ki67结果以及临床病理变量进行比较。
在97例乳腺癌病例中，66例（68%）为浸润性导管癌。平均年龄为54.3岁（最小25岁，最大100岁），平均肿瘤大小为31.1毫米（最小7毫米，最大120毫米）。58%的病例检测到淋巴结转移。在77例可获取远处转移数据的病例中，11例被诊断为有转移。11例因乳腺癌失访。随着肿瘤分级增加，远处转移和淋巴结转移的可能性也增加（分别为p = 0.04，p = 0.05）。病例的平均随访时间为26.6±9.8个月（最短6个月，最长53个月），其他变量之间的生存率无显著差异。副纤维蛋白检测结果显示，21.6%为阴性，9.3%为（+）阳性，11.3%为（++）阳性，57.7%为（+++）阳性。发现Ki67增殖指数与淋巴结转移及副纤维蛋白表达之间呈负相关（分别为p = 0.018，p = 0.029）。
我们认为副纤维蛋白可能是乳腺癌的一个潜在预后和预测参数。由于文献中关于此事的数据有限，进一步研究该问题并评估其与更大样本系列生存情况的关系将是有益的。
